Introduction
T ypical atrial flutter (AFL) is the second most common arrhythmia after atrial fibrillation (AF) and is associated with increased mortality rate and increased risk of thromboembolism or heart failure. 1 Due to its high efficacy and safety, percutaneous catheter-ablation (CA), has become the first treatment option for patients with typical AFL. 2 Ablation of typical AFL using radiofrequency (RF) current is based on the creation of transmural and complete necrotic lesion over the entire isthmus between the base of the right ventricle and the inferior vena cava. 3 The application of advanced technologies in recent years, such as externally irrigated-tip catheters, has shortened the procedure and reduced the AFL recurrence. 4 Identification of time frame of AFL recurrences as well as potential predictors of AFL recurrence after RF-CA could be clinically useful for identifying the patients who require multiple procedures and the continuation of antiarrhythmic drug therapy after the ablation. We analyzed the incidence and predictors of AFL recurrence after a typical AFL ablation in a set of more than 300 consecutive procedures, starting from the introduction of irrigation RF technology in our center.
Methods
This primary clinical observational study included all adult patients who underwent RF-CA of typical AFL using the externally irrigated-tip catheters in the period from January 2007 to December 2013 in Clinical Centre of Serbia. Data were collected from patients' histories, the electrophysiology (EP) laboratory electronic database and the protocols fulfilled during the clinical follow-up after the procedure. P-wave was determined by reading a standard 12-lead ECG with a typical AFL. The P-wave amplitude was measured from nadir to peak of the P-wave in inferior leads with standard ECG calibration at 10 mm/mV and speed of 25 mm/s. 6 AFL was classified as paroxysmal or persistent if the AFL episode lasted <7 days or ≥7 days, respectively 1 . Heart failure was defined as the presence of ≥2 of the following criteria: (1) left ventricular systolic dysfunction (ejection fraction <55%), (2) functional New York Heart Association (NYHA) class ≥2, (3) history of congestive heart failure before the procedure and (4) the administration of drug therapy for chronic heart failure 7 . Hyperlipoproteinemia (HLP) was diagnosed if abnormally elevated blood levels of any or all lipids were found (i.e. total cholesterol >5.2 mmol/L and triglicerides >2.2 mmol/L). Administration of general analgesia/sedation with midazolam, fentanyl and/or propofol was carried out during the procedure under the supervision of an anesthesiologist.
Ablation procedure. During all of the procedures noninvasive measurement of arterial blood pressure was performed every five minutes along with continuous noninvasive monitoring of pulse oximetry. Ablation of typical atrial flutter was described in details elsewhere. 8 Via the right femoral vein and under the guidance of fluoroscopy, diagnostic quadripolar catheter was inserted into the distal coronary sinus (CS), duodecapolar (HALO-like) catheter was positioned on inferolateral right atrial wall and 3.5-4 mm irrigated-tip ablation catheter was positioned at cavo-tricuspid isthmus. Linear ablation of isthmus consisted of point by point RF applications during pull-back of the ablation catheter from the right ventricle toward the inferior vena cava. At each site RF delivery lasted from 40 sec to 120 sec or until the local atrial electrogram amplitude reduction of >80%. Ablation started at central isthmus (i.e. at 18h in left oblique anterior projection) and, if needed, it was continued at septal and/or lateral isthmus until AFL termination and isthmus-block were achieved (Figure 2A) . Ablation was performed in the temperature mode with Definitions. Diagnosis of typical AFL was established based on the characteristic electrocardiographic (ECG) pattern with negative P-waves in the inferior leads and positive P-waves in lead V 1 (Figure 1) . 5 Amplitude of the the set-up of 43°C and 30-50W (the irrigation flow rate was 17 mL/min for applications ≤30W and 25-30 mL/ min for applications of >30W). RF delivery was immediately terminated in the case of any increase in impedance, or its decrease by >10-15 Ω. The criteria used to identify isthmus-block were: (1) craniocaudal atrial activation sequence along the duodecapolar catheter during CS pacing, (2) interval across the isthmus of ≥140 ms, and (3) corridor of widely separated (doubled) atrial potentials ≥90 ms along the entire ablation line ( Figure  2B ) 3 . After the last RF application the patient was monitored for 30 minutes before sheaths removal, and in the case of acute isthmus re-conduction, additional RF ablation was applied until stable conduction block across the isthmus was confirmed.
Anticoagulation. Unfractionated heparin was administered intravenously during persistent AFL ablation (bolus of 5000 i.u.). In all patients receiving oral anticoagulant therapy before procedure, the strategy of interrupted warfarin and bridging with subcutaneous low weight molecular heparin was applied. The procedure was performed when INR was below 1.5. Four hours after hemostasis, subcutaneous heparin was reintroduced, which was also done the following day with the oral anticoagu- lant, with bridging until the International Normalized Ratio (INR) reached the value of ≥2. Postoperatively, the oral anticoagulation therapy was prescribed to all patients for 1 month after the ablation and thereafter only to patients with CHADS 2 score of ≥2.
Follow-up after ablation. After the procedure, all patients were followed in the outpatient clinic with regular ECG examinations at 1, 3, 6 and 12 months after the procedure, and subsequently once per year. In symptomatic patients every effort was made to identify the potential AFL recurrence. In these patients 24-48h Holter-monitoring was performed or the patients were admitted to hospital for additional heart rhythm monitoring. 1, 5 Statistical analysis. Continuous variables are presented as mean (±1SD) and categorical variables are summarized as percentages. The association of clinical and procedural variables presented in Table 2 with the AFL recurrence after the ablation was analysed using univariate and multivariable Cox proportional hazards model. The actuarial probability of freedom from AFL after isthmus ablation was calculated and graphically presented with the method of Kaplan and Meier. Differences between the curves were tested for significance by the log rank statistic.
The value of p<0.05 was considered to be statistically significant. Statistical analysis was performed with the SPSS software, version 18.0.
Results
The study group consisted of 248 patients (the mean age was 57.4 ± 11.6 years and 180 [72.6%] were male). Baseline patients' characteristics are presented in detail in Table 1 . Structural heart disease and co-morbidities were diagnosed in 139 (56.0%) and 193 (77.8%) patients, respectively. Associated atrial fibrillation was documented in 110 (44.4%) patients and heart failure in 89 (35.9%) patients.
Total of 248 patients underwent 303 AFL ablation procedures. Fifthy five redo procedures were performed in 45 patients (1 to 4 times per patient). Primary success rate of the first and repeated procedure was 83.1% and 92.7% (p=0.095). The mean number of RF applications was significantly higher (23.1 ± 14.5 vs. 18.5 ± 11.6, p=0.013), and RF time (20.8 ± 12.6 min vs. 16.0 ± 9.7 min, p=0.002) as well as fluoroscopy time (15.9 ± 9.4 min vs. 12.2 ± 7.0 min, p=0.002) were significantly longer in the first compared to redo ablation. Major complications were registered in 1.7% (5/303) of procedures, including: two cases of hemodynamically stable pericardial effusion treated conservatively, two complications at vascular access site (one arteriovenous fistula surgically treated and one large groin hematoma that required blood transfusion) and one high grade AV block in patient with already implanted biventricular pacemaker.
During the mean follow-up time of 17.6 ± 14.7 months, 22.6% of patients (56/248) had AFL recurrence following the first procedure, but after the last ablation, recurrence of AFL was recorded in only 5.7% of patients (14/248). Recurrences of paroxysmal AFL and persistent AFL were recorded in 28 (50.0%) and 28 (50.0%) patients after the first ablation, and in 10 (71.4%) and 4 patients (28.6%) after the last ablation, respectively. In Figure 3 , Kaplan-Meyer curves show significant difference in the AFL recurrence after the first and the last ablation procedure (log rank p<0.001).
The mean time from ablation to AFL recurrence was 8.1 ± 6.4 months; the shortest time to recurrence was 1 day and the longest time was 33 months. The vast majority of recurrences of arrhythmia (48/66, 72.7%) occurred in the first year after ablation, the recurrence rate was low during further follow-up to the end of the study (Figure 4) . On univariate analysis (Table 2), the recurrence of AFL was significantly more frequent in younger patients, higher AFL P-wave amplitude on standard ECG, HLP, smaller left atrium size, longer fluoroscopy time, and significantly less frequent in in case the stable isthmus block has been achieved during ablation (p<0.001), with procedures performed by operator with experience of >100 AFL ablations and with procedures performed under general analgosedation of the patient. Multivariable analysis showed that patient age (Hazard Ratio [HR] 0.95; 95% Confidence Interval [CI], 0.93 -0.98, p<0.001), stable isthmus block at the end of procedure (HR: 0.22; 95% CI, 0.10 -0.46, p<0.001) and HLP diagnosis (HR 2.00; 95% CI, 1.00 -2.99, p=0.049) were independently associated with postprocedural recurrence of AFL ( Table 2) . Using ROC analysis the age of 56.5 years was determined as a cutt-off value that best discriminated patients with and without AFL recurrence after ablation (area under curve: 0.33; 95% CI, 0.26 -0.40, p<0.001). Figure 5 displays Kaplan-Meier analysis of AFL recurrence-free rate in patients of <56.5 years and ≥56.5 years at procedure and Figure 6 the cumulative probability of freedom from AFL following ablation procedures completed with and without stable isthmus-block. Figure 7 shows the freedom from AFL after ablation procedure in patients with or without hyperliporpoteinemia. During the follow-up after AFL ablation, atrial fibrillation was recorded in 31.0% (77/248) of patients and 199 (80.2%) patients were on antiarrhythmic drugs (41.9% patients were on amiodaron).
Discussion
The main finding of our study were: (1) majority of AFL recurrences were recorded during the first 6-12 months after ablation, and (2) variables such as (in)complete isthmus ablation, hyperlipoproteinemia and younger patient age were independently associated with recurrence of AFL after procedure.
Mechanism and time frame of AFL recurrence after ablation. Recent meta-analysis, including almost 10.000 patients undergoing irrigated RF ablation of AFL, dem- Figure 3 . Kaplan-Meier estimates of atrial flutter recurrence after the first and after the last ablation. Outcome after the last procedure was significantly better than after the first procedure (log rank p<0.001). onstrated the AFL recurrence rate of 11% 4 . The recurrence rate in our study was twice as high, probably due to the learning curve during the introduction of the irrigated RF technology in our center. 9 However, after the last procedure AFL recurrence was observed in only 5.7% of our patients.
No significant increase in the rate of AFL recurrence was recorded after 6 months following isthmus ablation. 4 In fact, after isthmus ablation, AFL recurrence rate in studies with different follow-up period was constant. Thus the incidence of recurrence with a follow-up of 6 months was 9.8%, 12 months 14.5%, 24 months 11.1%, 36 months 10.6% and >36 months 14.6%. 4 In one study with a minimum follow-up of 3 years after the procedure, 73% of all AFL recurrences was registered in the first 6 months after ablation, while the remaining 27% of recurrences was observed over a period of 6 months to 2 years after the procedure. 10 Our results are in line with these findings. This is in contrast with the finding of progressive and cumulative increase in the rate of AF recurrence after ablation of AF by about 10% annually in the first five years after the procedure.
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Atrial flutter is macroreentrant atrial tachycardia, depending on a clearly defined anatomical substrate, i.e. cavotricuspid isthmus. 1, 5 Therefore it is expected that complete isthmus ablation will lead to permanent elimination of the arrhythmia. Incomplete ablation of isthmus or postprocedural recovery of trans-isthmus conduction due to edema resolution may be responsible for clinical AFL recurrence. 12, 13 However, the mechanism and the substrate of AF are much more complex, and AF ablation strategy is largely based just on isolation of AF triggers from the pulmonary veins. 14 The presence of associated comorbidities such as aging, hypertension, diabetes etc. may lead to the subsequent evolution of the AF substrate after ablation, increasing the risk of arrhythmia recurrence.
14 Risk factors for AFL recurrence. In our study, AFL recurrence after ablation was significantly more frequent with younger age, higher P-wave amplutude of AFL on standard ECG, smaller left atrium size and HLP, while the recurrences of AFL were less frequent if the procedure was performed under general analgosedation and by more expirienced operators, with ablations completed with isthmus-block and procedures with shorter fluoroscopic time. The independent predictors of AFL recurrence after ablation were younger patient age, HLP and incomplete isthmus ablation. Other studies have identified the complex isthmus anatomy (i.e. prominent Eustachian ridge), dilated right atrium, prolonged procedural and fluoroscopic time and incomplete isthmus ablation as potential predictors for AFL recurrence. 12, 13, 15 Bidirectional isthmus block represents and EP surrogate of its transmural necrotic lesion. 3 Clinical recurrences of AFL were significantly less frequent in recent studies in which the ablation endpoint was isthmusblock, compared to historical studies where the endpoint was only AFL noninducibility after isthmus ablation (7% vs 26%). 4, 13 It has been already recognized by other authors that the patient age may affect the risk of arrhythmia recurrence after successful RF ablation of certain arrhythmogenic substrates. 16, 17 The patients with atrioventricular nodal reentrant tachycardia recurrence after slow pathway ablation were significanly younger compared with patients without tachycardia recurrence (43.8 ± 16.9 yeras. vs. 53.0 ± 15.2 years). 16 In addition, after typical AFL ablation, recurrence rate was significantly higher in patients aged <70 years than in older patients (9.0% vs. 14.8%). 17 It was suggested that younger patients may have a greater capacity for tissue regeneration after thermally-mediated RF ablation. In addition, it is possible that the operator uses less aggressive approach for ablation of the substrate in younger patients, in order to avoid complications. 16 Our study confirmed these findings. We identified the age of <56.5 years as the value that best differentiate patients at high risk for AFL recurrence after ablation.
The causes of higher AFL recurrence rate after ablation in patients with HLP in our study are not clear. AFL and AF are related arrhythmias and often coexist in the same patient. 1, 5 It has been shown that AF often appears as a transitional tachyarrhythmia shortly before the organization to typical AFL. 18 Patients with metabolic syndrome (central obesity, hypertension, dyslipidemia and impaired glucose tolerance) compared to those without the syndrome have an increased risk of AF recurrence after left atrial ablation procedure. 19 The complex interplay between the inflammation, collagen deposition in the myocardium and abnormal fatty acid metabolism could be responsible for the evolution of substrate that favors the development of atrial tachyarrhythmias in patients with dyslipidemia. 20 
Conclusion
Incidence of AFL recurrence after the first RF-CA of cavo-tricuspid isthmus in our study was around 20%. However, after the last procedure it was observed in less than 6% of our patients. Clinical recurrences of AFL mostly occur in the first 6-12 months after the procedure, although very late recurences are possible. The independent predictors of AFL recurrence after ablation were younger patient age, diagnosis of HLP and incomplete ablation of isthmus.
